Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Arterial prosthesis – Drug delivery
Reexamination Certificate
2004-02-18
2010-10-05
Pellegrino, Brian E. (Department: 3738)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Arterial prosthesis
Drug delivery
C623S001460
Reexamination Certificate
active
07806924
ABSTRACT:
Medical devices, and in particular implantable structures, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3959078 (1976-05-01), Guire et al.
patent: 4350160 (1982-09-01), Kolesov et al.
patent: 4366819 (1983-01-01), Kaster
patent: 4368736 (1983-01-01), Kaster
patent: 4624257 (1986-11-01), Berggren et al.
patent: 4722906 (1988-02-01), Guire et al.
patent: 4733665 (1988-03-01), Palmaz
patent: 4739762 (1988-04-01), Palmaz
patent: 4776337 (1988-10-01), Palmaz
patent: 4917090 (1990-04-01), Berggren et al.
patent: 4917091 (1990-04-01), Berggren et al.
patent: 5229172 (1993-07-01), Cahalan et al.
patent: 5234447 (1993-08-01), Kaster et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5350800 (1994-09-01), Cahalan et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5516781 (1996-05-01), Morris et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 6099562 (2000-08-01), Ding et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6425898 (2002-07-01), Wilson et al.
patent: 2003/0036794 (2003-02-01), Ragheb et al.
patent: 2003/0060877 (2003-03-01), Falotico et al.
patent: 2003/0216699 (2003-11-01), Falotico
patent: 2005/0136090 (2005-06-01), Falotico et al.
patent: 2005/0166841 (2005-08-01), Robida
patent: 1127582 (2001-08-01), None
patent: WO 98/33443 (1998-08-01), None
patent: WO 01/87372 (2001-11-01), None
European Search Report EP 05250908 dated May 25, 2005.
Clowes, A.W and Karnovsky M., Nature 265:25-26, 1977.
Guyton, J.R. et al., Circ. Res., 46:625-634, 1980.
Clowes, A.W. and Clowes, M.M., Lab. Invest. 52:611-616, 1985.
Clowes, A.W. and Clowes, M.M., Circ. Res. 58:839-845, 1986.
Majesky et al., Circ. Res. 61:296-300, 1987.
Snow et al., Am. J. Pathol. 137:313-330, 1990.
Okada T. et al., Neurosurgery 25: 92-98, 1989.
Currier, J.W. et al., Circ. 80:11-66, 1989.
Sollot, S.J. et al., J. Clin. Invest. 95: 1869-1876, 1995.
Powell, J. S. et al., Science, 245: 186-188, 1989.
Lundergan, C. F. et al., Am J. Cardio. 17 (Suppl. B): 132B-136B, 1991.
Jonasson, I. et al., Proc. Natl., Acad. Sci., 85: 2303, 1988.
Ferns, G.A.A., et al., Science 253: 1129-1132, 1991.
Nemecek, G.M. et al., J. Pharmacol Exp.Thera. 248: 1167-1174, 1989.
Liu, M.W. et al., Circ. 81: 1089-1093, 1990.
Fukuyama, J. et al., Eur. J. Pharmacol. 318: 327-332, 1996.
Hansson, G.K. and Holm, J. Circ. 84: 1266-1272, 1991.
Marx, S.O. et al., Circ. Res. 76: 412-417, 1995.
Colburn, M.D. et al., J. Vasc. Surg. 15: 510-518, 1992.
Berk, B.C. et al., J. Am. Coll. Cardiol. 17: 111B-117B, 1991.
Weinberger, J. et al., Int. J. Rad. Onc. Biol. Phys. 36: 767-775, 1996.
Farb, A. et al., Circ. Res. 80:542-550, 1997.
Simons, M. et al., Nature 359: 67-70, 1992.
Chang, M.W. et al., J. Clin. Invest. 96: 2260-2268, 1995.
Modern Fluoropolymers, (J Shires ed.), John Wiley & Sons, New York, 1997, pp. 77-87.
Ajroldi, et al., Fluoroelastomers-dependence of relaxation Phenomena on Compositions, Polymer 30, 2180, 1989.
Hanson & Harker, Proc. Natl. Acad. Sci. USA 85:3184-3188, 1988.
Woo et al., J. Med Chem, 45:2877-2885, 2002.
Deroanne et al., Ooncogene 21(3): 427-436, 2002.
Beutler, E., et al. “Cladribine (2-Chlorodeoxyadenoisine)”, The Lancet (1992) vol. 340, pp. 952-956.
Campbell & Campbell, “Phenotypic Modulation of Smooth Muscle Cells in Primary Culture” (Table of Contents), Chapter 4, vol. 1, pp. 39-52 (1985).
Campbell and Campbell “Cell Biology of Smooth Muscle in Culture: Implications for Atherogenesis”, Inter. Angio, 6, pp. 73-79 (1987).
Carrera, C., et al. “Potent Toxicity of 2-Chlorodeoxyadenoisine Toward Human Monocytes in Vitro and in Vito”, J. Clinical Investigation vol. 86 pp. 1480-1488 (1990).
Carson, D., et al. “Specific Toxicity of 2-Chlorodeoxyadenosine Toward Resting and Proliferating Human Lymphocytes”, Blood, vol. 62, No. 4, pp. 737-743 (1983)62 pp. 737-743 (1983).
Carson, D., et al. “Lymphocyte Dysfunction After DNA Damage by Toxic Oxygen Species”, J. Exp. Medicine, vol. 163 (Mar. 1986) pp. 745-751.
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury”, Laboratory Investigation, vol. 52, No. 6, pp. 611-616 (1985).
Edelman, E., et al. “Pathobiologic Responses to Stenting”, American Journal of Cardiology, vol. 81, Issue 7, Suppl. 1 (Apr. 1998) pp. 4E-6E.
Fischman, D., et al. “A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease”, The New England Journal of Medicine, vol. 331, pp. 496-501 (1994).
Franklin, S., et al. “Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials”, Coronary Artery Disease, vol. 4, No. 3 pp. 232-242 (Mar. 1993).
Lang R., et al. “Effects of Okadaic Acid and ATPγS on Cell Length and CA2+-Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci”, Br. J. Pharmacol. 104, pp. 331-336 (1991).
Mak and Topol, K., et al. “Clinical Trials to Prevent Restenosis After Percutaneous Coronary Revascularization”, Department of Cardiolg. Cleveland Clinical Foundation, Ohio pp. 255-288 (1991).
Mintz, G., et al. “Limitations of Angiography in the Assessment of Plaque Distribution in Coronary Artery Disease”, Circulation, vol. 93 pp. 924-932 (1996).
Mintz, G., et al. “Arterial Remodeling After Coronary Angioplasty: A Serial Intravascular Ultrasound Study”, Circulation, vol. 94(1) pp. 35-43 (1996).
Mintz, G., et al. “Intravascular Ultrasound Predictors of Restenosis After Percutaneous Transcatheter Coronary Revascularization”, JACC, vol. 27(7) pp. 1678 (1996).
Pompa, J., et al. “Clinical Trials of Restenosis After coronary Angioplasty”, American Heart Association, Circulation, (1991) 84 pp. 1426-1436.
Serruys, P., et al. “Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized Double-Blind Placebo-Controlled Trial”, American Heart Association, Circulation 88 (1993) pp. 1588-1601.
Serruys, P., et al. “A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease”, New England Journal of Medicine, vol. 33 pp. 489-495 (1994).
Serruys, P., et al. “Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study”, Circulation of the American Heart Association, vol. 93(3) pp. 412-422 (1996).
Seto, S., et al. “Mechanism of Doxygadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes”, J. Clinical Investigation, vol. 75 (Feb. 1985) pp. 37-383.
Tanaka, H., et al., “Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury”, Circulation, vol. 88, pp. 1788-1803 (1993).
Tardif, J-C., et al. “Probucol and Multivitamins in the Prevention of Restenosis After Coronary Angioplasty”, New England Journal of Medicine, vol. 33, pp. 365-372 (1997).
Teirstein, P., et al. “Catheter-Based Radiotherapy to Inhibit Restenosis After Coronary Stenting”, vol. 336, No. 24 (Jun. 1997) pp. 1679-1703.
Yokoi, H., et al. “
Falotico Robert
Parry Tom Jay
Zhao Jonathon Z.
Cordis Corporation
Evans Carl
Pellegrino Brian E.
LandOfFree
Implantable structures for local vascular delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Implantable structures for local vascular delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Implantable structures for local vascular delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4238860